Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jennifer Erdman"'
Autor:
Garrett L. Robinson, Erin Willert, Jack P. Higgins, Sangeetha Rajagopalan, Brigitte Brieschke, Jennifer Erdman, William Null
Publikováno v:
Cancer Research. 75:P4-15
The HER2 receptor is overexpressed in 20-30% of breast cancers. HER2 overexpression in breast cancer has been successfully targeted by both antibody and antibody-drug conjugate (ADC) approaches. The recently approved trastuzumab-emtansine (T-DM1, Kad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df97489205e11ca97f35824cc574057c
https://doi.org/10.1158/1538-7445.sabcs14-p4-15-17
https://doi.org/10.1158/1538-7445.sabcs14-p4-15-17
Autor:
Garrett L. Robinson, Brigitte Brieschke, Jennifer Erdman, Sangeetha Rajagopalan, Jane Neill, Rodney Flores, Jack P. Higgins, Jensing Liu, Erin Willert
Publikováno v:
Cancer Research. 77:2659-2659
Molecular Templates is developing engineered toxin bodies (ETBs), potent recombinant immunotoxins that combine the specificity of an antibody fragment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit (SLTA). ETBs can induce the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e7f27095cd4b7f840fc24c30b641646
https://doi.org/10.1158/1538-7445.am2017-2659
https://doi.org/10.1158/1538-7445.am2017-2659
Autor:
Brigitte Brieschke, Rodney E. Flores-Lefranc, Jensing Liu, Erin Willert, Julia Foree, Garrett L. Robinson, Sangeetha Rajagopalan, Jack P. Higgins, William Null, Jennifer Erdman, Jane Neill
Publikováno v:
Cancer Research. 76:1483-1483
Molecular Templates has developed engineered toxin bodies (ETBs), potent recombinant immunotoxins that combine the specificity of an antibody fragment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit to specifically destroy tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b1cb1536c71a2cf3b7a2b36032f1bf1
https://doi.org/10.1158/1538-7445.am2016-1483
https://doi.org/10.1158/1538-7445.am2016-1483
Autor:
Sangeetha Rajagopalan, Erin Willert, Brigitte Brieschke, Jennifer Erdman, Garrett L. Robinson, Jack P. Higgins, Jane Neill
Publikováno v:
Cancer Research. 76:595-595
Molecular Templates is developing engineered toxin bodies (ETBs), potent recombinant immunotoxins that combine the specificity of an antibody fragment with the powerful direct cytotoxicity of the Shiga-like toxin A subunit to specifically kill target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5626172fc30a7052ecd9a8827dbcf97e
https://doi.org/10.1158/1538-7445.am2016-595
https://doi.org/10.1158/1538-7445.am2016-595
Autor:
Jensing Liu, Jane Neill, Rodney Flores, Garrett L. Robinson, William Null, Erin Willert, Julia Foree, Jennifer Erdman, Brigitte Brieschke, Jack P. Higgins, Sangeetha Rajagopalan
Publikováno v:
Clinical Cancer Research. 21:A15-A15
The cell surface glycoprotein CD38 is highly expressed on the surface of several B cell lineage cancers, such as the plasma cell malignancy multiple myeloma, some lymphomas and chronic lymphocytic leukemia (CLL), where it is a marker of unfavorable p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bf359e46c1ffecbcb95e124ab77ebb6
https://doi.org/10.1158/1557-3265.hemmal14-a15
https://doi.org/10.1158/1557-3265.hemmal14-a15
Autor:
Garrett L. Robinson, William Null, Brigitte Brieschke, Jensing Liu, Erin Willert, Julia Foree, Jane Neill, Rodney Flores, Jack P. Higgins, Sangeetha Rajagopalan, Jennifer Erdman
Publikováno v:
Cancer Research. 75:2477-2477
The potential of immunotoxins in oncology has been largely limited due to problems with immunogenicity as well as a limited number of appropriate targets. Advances in genetic engineering and molecular biology have been applied to overcome these limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cc05ad769e19c50fc8d2390a0063cd5
https://doi.org/10.1158/1538-7445.am2015-2477
https://doi.org/10.1158/1538-7445.am2015-2477
Autor:
Brigitte Brieschke, Jennifer Erdman, Erin Willert, Jack P. Higgins, Sangeetha Rajagopalan, Garrett L. Robinson, William Null
Publikováno v:
Cancer Research. 74:671-671
Multiple myeloma is a malignancy of plasma cells that accounts for 10% of all hematological cancers. Current treatments for multiple myeloma include immunomodulatory agents, protease inhibitors and chemotherapies and, while these therapies are often
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b18ce2e048af03a798047c45635f2963
https://doi.org/10.1158/1538-7445.am2014-671
https://doi.org/10.1158/1538-7445.am2014-671
Autor:
Rodney Flores, Rachel Wirth, Jensing Liu, William Null, Jennifer Erdman, Kari Grant, Jack P. Higgins, Erin Willert, Brigitte Brieschke, Sangeetha Rajagopalan
Publikováno v:
Cancer Research. 74:647-647
The B-cell membrane protein CD20 is expressed by both benign and neoplastic lymphocytes. It has been a superb target for immunotherapies targeting B-cell derived diseases. There are several anti-CD20 antibodies which have been developed for B-cell ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5136f35a3adaf0a88bf599d14528d0d
https://doi.org/10.1158/1538-7445.am2014-647
https://doi.org/10.1158/1538-7445.am2014-647
Autor:
Erin Willert, Rachel Wirth, William Null, Jensing Liu, Sangeetha Rajagopalan, Jennifer Erdman, Jack P. Higgins
Publikováno v:
Cancer Research. 73:5477-5477
Non-Hodgkin's lymphoma (NHL) offers an attractive area for therapeutic biologics. The most successful example of this targeted approach is rituximab, which is approved for front and second line therapy of NHL. Rituximab targets the CD20 antigen expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c614c4932af1d3d8fb7ffb3156c67fed
https://doi.org/10.1158/1538-7445.am2013-5477
https://doi.org/10.1158/1538-7445.am2013-5477